Weight-Loss drug pregnancy risks under investigation
NCT ID NCT05872022
Summary
This study is collecting information about pregnancy outcomes for women who take Wegovy (semaglutide) for weight management. Researchers will compare about 728 pregnant women who take Wegovy with similar women who don't take the medication. They'll track birth outcomes, complications during pregnancy, and infant development through the baby's first year to understand potential risks.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PREGNANCY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novo Nordisk Investigational Site
Princeton, New Jersey, 08540, United States
-
Novo Nordisk Investigational Site
Madrid, Spain
-
Novo Nordisk Investigational Site
London, United Kingdom
Conditions
Explore the condition pages connected to this study.